^
    1d
    Safety and efficacy of hepatic arterial infusion chemotherapy combined with camrelizumab and apatinib for advanced hepatocellular Carcinoma: a retrospective clinical analysis. (PubMed, Clin Res Hepatol Gastroenterol)
    Together, HAIC combined with camrelizumab and apatinib demonstrated favorable efficacy and acceptable safety in patients with advanced HCC. This combination regimen may represent a promising therapeutic strategy for advanced HCC.
    Retrospective data • Journal • PD(L)-1 Biomarker
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • AFP (Alpha-fetoprotein) • CA 19-9 (Cancer antigen 19-9)
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    1d
    Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC (clinicaltrials.gov)
    P2, N=160, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • Sulanda (surufatinib)
    2d
    Camrelizumab, a patinib and radiotherapy in locally advanced, unresectable hepatocellular carcinoma: a phase 2 study. (PubMed, Clin Cancer Res)
    Camrelizumab and apatinib with radiotherapy demonstrated encouraging efficacy with manageable toxicity in locally advanced, unresectable HCC, warranting randomized trials validation.
    P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    7d
    A Study on the Efficacy and Safety of Sintilimab Combined With Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients With Short-term Recurrence After Adjuvant Therapy (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    paclitaxel • Tyvyt (sintilimab) • Cyramza (ramucirumab)
    8d
    Theranostic potential of ramucirumab functionalized magnetoliposomes for targeted delivery of sorafenib and MRI. (PubMed, J Pharm Sci)
    Moreover, treatment of HepG2 cells with S-MLPs led to a 12.99-fold increase in the activity of apoptotic proteins and decreased production of angiogenic proteins from 331.57 to 83.34 pg mL-1. The R2 relaxation value of 57.262 mM-1 s-1 obtained for the MLPs, indicating their high potential for clinical cancer management.
    Journal
    |
    KDR (Kinase insert domain receptor)
    |
    sorafenib • Cyramza (ramucirumab)
    8d
    Paclitaxel plus ramucirumab and tislelizumab as switch maintenance versus continuation of chemotherapy and tislelizumab in patients with advanced HER2-negative and PD-L1 positive gastroesophageal adenocarcinoma: the ARMANI-2/ENGIC08 trial by GONO (2025-524048-36-00)
    P2/3, N=212, Not yet recruiting, Gruppo Oncologico Del Nord Ovest
    New P2/3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    |
    cisplatin • paclitaxel • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • Cyramza (ramucirumab) • oxaliplatin • leucovorin calcium
    8d
    Real-world treatment patterns, resource use, and costs in human epidermal growth factor receptor 2-negative advanced gastric/gastroesophageal junction cancer in the United States in the immune checkpoint inhibitor era. (PubMed, J Manag Care Spec Pharm)
    Across both databases, chemotherapy was the most common 1L regimen (approximately 50%), followed by nivolumab-containing regimens (34.7% in Medicare; 44.2% in MarketScan) and pembrolizumab-containing regimens (9.9% and 5.3%, respectively)...Nivolumab-containing regimens were the most common 2L treatment (36.3% in Medicare; 41.3% in MarketScan), whereas ramucirumab-containing regimens were most common in 3L (36.7% and 34.0%, respectively)...Analyses of recent data from the Medicare and MarketScan databases showed that most treated patients with HER2-negative advanced G/GEJC received standard chemotherapy in the 1L setting. Treatment of advanced G/GEJC remains associated with poor rwOS and high economic burden, suggesting significant remaining unmet need.
    Observational data • Retrospective data • Journal • HEOR • Checkpoint inhibition • Real-world evidence • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Cyramza (ramucirumab)
    11d
    Paclitaxel plus ramucirumab and tislelizumab as switch maintenance versus continuation of chemotherapy and tislelizumab in patients with advanced HER2-negative and PD-L1 positive gastroesophageal adenocarcinoma: the ARMANI-2/ENGIC08 trial by GONO (2025-524048-36-00)
    P2/3, N=172, Not yet recruiting, Gruppo Oncologico Del Nord Ovest
    New P2/3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    |
    cisplatin • paclitaxel • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • Cyramza (ramucirumab) • oxaliplatin • leucovorin calcium
    14d
    Ramucirumab induces apoptosis in Caco-2 cells via mitochondrial impairment and caspase activation. (PubMed, Saudi Pharm J)
    In conclusion, by causing cell cycle arrest and inducing apoptosis via mitochondrial malfunction and caspase pathway activation, ramucirumab demonstrates anti-cancer action against Caco-2 cells. These findings provide new perspectives on ramucirumab's wider anti-tumor potential beyond angiogenesis inhibition.
    Journal
    |
    CASP3 (Caspase 3) • CASP7 (Caspase 7)
    |
    Cyramza (ramucirumab)
    15d
    ACADEMY: A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC (clinicaltrials.gov)
    P2, N=38, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Trial completion date: Oct 2027 --> Oct 2028 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    AiTan (rivoceranib) • AiRuiLi (adebrelimab)
    20d
    A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer (clinicaltrials.gov)
    P1/2, N=48, Completed, Sun Yat-sen University | Not yet recruiting --> Completed | Trial completion date: Dec 2024 --> May 2026 | Trial primary completion date: Dec 2023 --> Dec 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    cisplatin • gemcitabine • AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    21d
    HMPL-012-SPRING-P105: Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, Tianjin Medical University Cancer Institute and Hospital | Trial completion date: May 2026 --> Dec 2026
    Trial completion date
    |
    gemcitabine • albumin-bound paclitaxel • Sulanda (surufatinib)